The use of surrogate markers in the antiretroviral treatment of HIV-1 infection
Hill, A.M.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Table of Contents

Chapter 1
Introduction ........................................................................................................................................5

Chapter 2
Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials
Schlomo Staszewski, Andrew M. Hill, John Bartlett, Joseph J. Eron, Christine Katlama, Judy Johnson, William Sawyer and Hugh McDade
AIDS 1997, 11: 477-483 ................................................................................................................11

Chapter 3
CD4 cell counts in seven laboratory workers
Andrew M. Hill, Theresa Ekong, Colin Clark, Mark Gompels, Anthony J Pinching

Chapter 4
Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine.
Milos Opravil, Andrew M Hill, Ralph DeMasi and Debra Dawson.
Antiviral Therapy 1998, 3: 169-176 ..............................................................................................27

Chapter 5
Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count
Clive Loveday, Andrew M. Hill,
Letter in the Lancet Vol. 345 March 25, 1995 .............................................................................41

Chapter 6
HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors
Schlomo Staszewski, Ralph DeMasi, Andrew M. Hill and Debra Dawson

Chapter 7
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count
Julio S.G. Montaner, Ralph DeMasi and Andrew M. Hill

Chapter 8
Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death
Andrew M Hill, Ralph DeMasi and Debra Dawson.
Antiviral Therapy 1999, 3: 139-145 ..............................................................................................67

Chapter 9
Analysis of HIV-1 clinical trials: statistical magic?
The AVANTI Steering Committee (corresponding author Andrew Hill)
The Lancet 1999; 353: 2061-64 .....................................................................................................79